Arcturus Therapeutics

Arcturus Therapeutics presented three core programs at the Cantor Global Healthcare Conference: ARCT-810 for OTC deficiency, an inhaled mRNA program for cystic fibrosis (CF), and a self-amplifying mRNA platform with commercial vaccine success. Near-term catalysts include the Phase II readout for ARCT-810 expected later this month, FDA feedback, and a fourth-quarter decision on whether to continue the CF program — a move that could trigger funding from Thermo Fisher. Management highlights technological advantages (biodegradable LNPs, improved mRNA purification, a tailored nebulizer) but still sees risks around efficacy, safety and competition. » Więcej na de.investing.com

At the Citigroup conference, Arcturus Therapeutics announced two near-term catalysts: Phase II data on OTC deficiency in September and a go/no-go decision on initiating Phase III for cystic fibrosis in the fourth quarter. The inhaled mRNA platform was presented as differentiated after safety and tolerability issues were addressed. Thermo Fisher has committed up to $40 million to non-dilutively support the Phase III cystic fibrosis development in exchange for exclusive manufacturing rights. The vaccine business provides non-dilutive revenue to fund the therapeutic pipeline; substantial CF data are expected in early 2025. » Więcej na de.investing.com

Arcturus Therapeutics’ stock rose intraday by about 10–13% after management announced participation in five major investor conferences in September, viewed as a vote of confidence in the pipeline. Key clinical milestones for ARCT-032 (cystic fibrosis) and ARCT-810 (OTC deficiency) are approaching. Analyst support, better-than-expected quarterly results, more than $191 million in cash and a strategic manufacturing agreement with Thermo Fisher bolster the funding outlook through 2028 and the credibility for a potential phase 3 study. The rally occurred despite a weaker broader market and appears to be company-specific. » Więcej na de.investing.com